Paul Kaesberg, M.D.
Professor of Medicine (HSCP)
To see if Paul Kaesberg is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Specialties
Geriatric Oncology
Benign and Malignant Hematology
Hematology/Oncology
Department
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Kaesberg is an adult medical hematologist who specializes in medical treatment of geriatric oncology as well as benign and malignant hematology. He is a strong advocate for providing patients with comprehensive care such as mutational profiling, regional therapies, clinical trials and supportive care.
Clinical Interests
Dr. Kaesberg is an adult hematologist who specializes in geriatric oncology as well as benign and malignant hematology.
Research/Academic Interests
Dr. Kaesberg is interested in conducting clinical trials for heme malignancies and has a particular interest in novel treatments for geriatric oncology as well as benign and malignant hematology including molecular targeted therapies, immunotherapies and therapies to overcome resistance.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.S., Biochemisty, Medical College of Wisconsin, Madison WI 1978
Medical School
M.D., University of Wisconsin Medical School, Madison WI 1982
Internship
Internal Medicine, Medical College of Wisconsin, Milwaukee WI 1982-1983
Residency
Internal Medicine, Medical College of Wisconsin, Milwaukee WI 1983-1985
Fellowship
Hematology, University of Wisconsin, Madison WI 1985-1987
Consultant Medical Director, Health Science and Nursing Projects-Sacramento City College, 2018, 2019, 2020, 2021, 2022
Teaching Award, University of Wisconsin, Hematology, 1988
American Cancer Society Fellowship, 1988
For a comprehensive list of Dr. Kaesberg's publications, please click here.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi:10.6004/jnccn.2022.0046. PMID:36075392.
Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 Aug;119:106885. doi:10.1016/j.leukres.2022.106885. Epub 2022 Jun 8. PMID:35738024.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022 Jun;20(6):622-634. doi:10.6004/jnccn.2022.0031. PMID:35714675.
Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 Sep 1;27(17):4726-4736. doi:10.1158/1078-0432.CCR-20-4622. Epub 2021 Jun 4. PMID:34088724.
Tuscano J, Poh C, Rosenberg A, Jonas B, Abedi M, Barisone G, Schwab E, Lundeberg K, Kaesberg P. Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia. J Hematol. 2020 Sep;9(3):79-83. doi:10.14740/jh721. Epub 2020 Aug 14. PMID:32855756.
Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma. 2020 Feb;61(2):309-317. doi:10.1080/10428194.2019.1672052. Epub 2019 Oct 16. PMID:31617432.
DeMartini J, Fenton JJ, Epstein R, Duberstein P, Cipri C, Tancredi D, Xing G, Kaesberg P, Kravitz RL. Patients' Hopes for Advanced Cancer Treatment. J Pain Symptom Manage. 2019 Jan;57(1):57-63.e2. doi:10.1016/j.jpainsymman.2018.09.014. Epub 2018 Sep 25. PMID:30261227.
DeMartini J, Fenton JJ, Epstein R, Duberstein P, Cipri C, Tancredi D, Xing G, Kaesberg P, Kravitz RL. Patients' Hopes for Advanced Cancer Treatment. J Pain Symptom Manage. 2019 Jan;57(1):57-63.e2. doi:10.1016/j.jpainsymman.2018.09.014. Epub 2018 Sep 25. PMID:30261227.
Epstein RM, Duberstein PR, Fenton JJ, Fiscella K, Hoerger M, Tancredi DJ, Xing G, Gramling R, Mohile S, Franks P, Kaesberg P, Plumb S, Cipri CS, Street RL Jr, Shields CG, Back AL, Butow P, Walczak A, Tattersall M, Venuti A, Sullivan P, Robinson M, Hoh B, Lewis L, Kravitz RL. Effect of a Patient-Centered Communication Intervention on Oncologist-Patient Communication, Quality of Life, and Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical Trial. JAMA Oncol. 2017 Jan 1;3(1):92-100. doi:10.1001/jamaoncol.2016.4373. PMID:27612178.
Hoerger M, Epstein RM, Winters PC, Fiscella K, Duberstein PR, Gramling R, Butow PN, Mohile SG, Kaesberg PR, Tang W, Plumb S, Walczak A, Back AL, Tancredi D, Venuti A, Cipri C, Escalera G, Ferro C, Gaudion D, Hoh B, Leatherwood B, Lewis L, Robinson M, Sullivan P, Kravitz RL. Values and options in cancer care (VOICE): study design and rationale for a patient-centered communication and decision-making intervention for physicians, patients with advanced cancer, and their caregivers. BMC Cancer. 2013 Apr 9;13:188. doi:10.1186/1471-2407-13-188. PMID:23570278.